
| Disease Domain | Count |
|---|---|
| Infectious Diseases | 6 |
| Neoplasms | 4 |
| Nervous System Diseases | 2 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 12 |
| Prophylactic vaccine | 3 |
| Monoclonal antibody | 1 |
| Drug conjugates | 1 |
| Genetically engineered subunit vaccine | 1 |
Target |
Mechanism Potassium channel blockers |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseIND Approval |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ACE2 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HDGFL1 inhibitors |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2025 |
Sponsor / Collaborator |
Start Date10 Aug 2025 |
Sponsor / Collaborator |
Start Date30 Nov 2024 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
GAP112-RBD ( SARS-CoV-2 S protein ) | Coronavirus Infections More | Preclinical |
HPK1 Inhibitors 2t(Central China Normal University) ( HPK1 ) | Neoplasms More | Preclinical |
GCS-12-6 | Inflammation More | Preclinical |
Pam3CSK4-RBD ( ACE2 ) | COVID-19 More | Preclinical |
DH4 ( SERT ) | Depressive Disorder More | Preclinical |





